diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM13326diaendo-13326Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL STUDIESКорреляция между уровнями ИФР-2 и ИФР-1 у пациентов с сахарным диабетом 1 типа в ИракеCorrelation between IGF-2 and IGF-1 levels in type 1 diabetic Iraqi patientshttps://orcid.org/0000-0002-8729-1642EltayefE. M.EltayefE. M.

Emad Mahmoud Eltayef, PhD in Biochemistry, Assistant Professor

Scopus Author ID: 57197834940

Багдад

Emad Mahmoud Eltayef, PhD in Biochemistry, Assistant Professor

Scopus Author ID: 57197834940

Baghdad

ema2006_1979@yahoo.comhttps://orcid.org/0000-0003-4879-3671GharbK.GharabK.

Karam Gharb, PhD in Biochemistry, Assistant lecturer

Scopus Author ID: 58705955800

Багдад

Karam Gharb, PhD in Biochemistry, Assistant lecturer

Scopus Author ID: 58705955800

Baghdad

karammazin@uomustansiriyah.edu.iqhttps://orcid.org/0009-0009-1067-6550GhannawiL. А.GhannawiL. A.

Lujain A. Ghannawi, MD in Biology, Assistant lecturer

Scopus Author ID: 58706394800

Багдад

Lujain A. Ghannawi, MD in Biology, Assistant lecturer

Scopus Author ID: 58706394800

Baghdad

lujainghannawi@uomustansiriyah.edu.iqhttps://orcid.org/0009-0004-8252-9967AttaS. E.AttaS. E.

Safaa Ehssan Atta, MD in Biotechnology, Assistant lecturer

Scopus Author ID: 7101843976

Baghdad, Palestine Street, 10064

Safaa Ehssan Atta, MD in Biotechnology, Assistant lecturer

Scopus Author ID: 7101843976 

Baghdad, Palestine Street, 10064

safaaehssan@uomustansiriyah.edu.iqhttps://orcid.org/0000-0003-2813-3879SalmanI. N.SalmanI. N.

Isam Noori Salman, Assistant Professor

Scopus Author ID: 57195920582

Багдад

Isam Noori Salman, Assistant Professor

Scopus Author ID: 57195920582

Baghdad

esamnoori61@gmail.comУниверситет Аль-Мустансирия/ Колледж наукИракCollege of Science, Mustansiriyah UniversityIraqУниверситет Аль-Мустансирия/Национальный центр диабетаИракNational Diabetes Center, Mustansiriyah UniversityIraq202626072026293269276Copyright © Eltayef E.M., Gharb K., Ghannawi L.А., Atta S.E., Salman I.N., 20262026Eltayef E.M., Gharb K., Ghannawi L.А., Atta S.E., Salman I.N.Eltayef E.M., Gharab K., Ghannawi L.A., Atta S.E., Salman I.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/13326ОБОСНОВАНИЕ

ОБОСНОВАНИЕ. Сахарный диабет 1 типа (СД1) — это аутоиммунное заболевание, характеризующееся нарушением функции β-клеток и дефицитом инсулина. Появляются новые данные, указывающие на нарушение регуляции оси инсулиноподобного фактора роста (ИФР) в его патофизиологии.

ЦЕЛЬ

ЦЕЛЬ. Изучить уровни общего ИФР-2 в сыворотке взрослых пациентов с СД1 в Ираке и корреляцию этих результатов с уровнями ИФР-1 и другими биохимическими параметрами.

МАТЕРИАЛЫ И МЕТОДЫ

МАТЕРИАЛЫ И МЕТОДЫ. Всего 160 участников, включая 80 пациентов с историей СД1 и 80 здоровых лиц в возрасте 18–30 лет, были набраны из Национального центра диабета, Университета Мустансирии. Все образцы крови из обеих групп были проанализированы на ИФР-1, уровень гликемии в крови натощак (ГПН), гликированный гемоглобин (HbA1c), липидный профиль и маркеры функции почек. В то же время ИФР-2 оценивался с помощью набора для иммуноферментного анализа.

РЕЗУЛЬТАТЫ

РЕЗУЛЬТАТЫ. Статистический анализ выявил значительные различия во всех изученных факторах между пациентами с СД1 и контрольными группами (p<0,001). Примечательно, что уровни ИФР-1 были значительно ниже у пациентов с СД1 (медиана 147 мг/дл) по сравнению с контрольной группой (медиана 215 мг/дл). Для сравнения, уровни ИФР-2 были заметно повышены у пациентов (медиана 1,15 мг/дл) по сравнению с контрольной группой (медиана 0,37 мг/дл). Сильные положительные корреляции наблюдались между ГПН, HbA1c и ИФР-2, тогда как отрицательные корреляции были обнаружены между этими параметрами и ИФР-1. Кроме того, ИМТ показал положительные ассоциации с ГПН, HbA1c и ИФР-2, но отрицательные ассоциации с ИФР-1 и соотношением ИФР-1/ИФР-2.

ЗАКЛЮЧЕНИЕ

ЗАКЛЮЧЕНИЕ. Эти результаты подчеркивают нарушение регуляции системы ИФР при СД1 и предполагают, что ИФР-1 и ИФР-2 могут служить потенциальными биомаркерами прогрессирования заболевания и метаболической дисфункции. Необходимы дальнейшие исследования для выяснения терапевтических последствий воздействия на ось ИФР при СД1.

BACKGROUND

BACKGROUND: Type 1 diabetes mellitus (T1D) is an autoimmune disorder characterized by impaired β-cell function and insulin deficiency, with emerging evidence implicating dysregulation of the insulin-like growth factor (IGF) axis in its pathophysiology.

AIM

AIM: This research aimed to explore the levels of total insulin-like growth factor-2 (IGF-2) in sera of Iraqi adult patients with T1D and correlate these findings with insulin-like growth factor-1 (IGF-1) levels and other biochemical parameters.

MATERIALS AND METHODS

MATERIALS AND METHODS: A total of 160 participants, including 80 patients with a history of T1D and 80 healthy controls were recruited from the National Diabetes Center, Mustansiriyah University. All Blood samples from both groups were analyzed for IGF-1, Fasting Blood Sugar (FBS), Glycated Hemoglobin (HbA1c), Lipid Profile, and Renal Function Markers. At the same time, IGF-2 was assessed via an enzyme-linked immunosorbent assay kit.

RESULTS

RESULTS: Statistical analysis shows significant differences in all studied factors between T1D patients and control groups (p< 0.001). Notably, IGF-1 levels were significantly lower in T1D patients (median: 147 mg/dl) compared to controls (median: 215 mg/dl). In comparison, IGF-2 levels were markedly elevated in patients (median: 1.15 mg/dl) versus controls (median: 0.37 mg/dl). Strong positive correlations were observed between FBS, HbA1c, and IGF-2, whereas negative correlations were found between these parameters and IGF-1. Additionally, BMI showed positive associations with FBS, HbA1c, and IGF-2 but negative associations with IGF-1 and IGF-1/IGF-2 Ratio.

CONCLUSION

CONCLUSION: These findings indicate significant changes in the IGF system in patients with T1D. In particular, changes in IGF-1 and IGF-2 levels are thought to be related to the metabolic disturbances seen in T1D. However, larger, long-term studies are needed to better understand the clinical significance and potential biological mechanisms of these results.

сахарный диабетИФР-1ИФР-2соотношение ИФР-1/ИФР-2diabetes mellitusIGF-1IGF-2IGF-1/IGF-2 ratioNo external funding was received for this work from any governmental, commercial, or non-profit organizations. The study was conducted using internal resources and the authors’ own input.ReferencesJia W, Chan JCN, Wong TY, et al. Diabetes in China: epidemiology, pathophysiology and multi-omics. Nature Metabolism. 2025;7(1):16–34. doi: https://doi.org/10.1038/s42255-024-01190-wJia W, Chan JCN, Wong TY, et al. Diabetes in China: epidemiology, pathophysiology and multi-omics. Nature Metabolism. 2025;7(1):16–34. doi: https://doi.org/10.1038/s42255-024-01190-wSalman IN, Mohammed NUG, Atta SE, et al. serum visfatin in patients with type 2 diabetes mellitus and diabetic retinopathy. Diabetes Mellitus. 2024;27(5):480–486. doi: https://doi.org/10.14341/dm13165Salman IN, Mohammed NUG, Atta SE, et al. serum visfatin in patients with type 2 diabetes mellitus and diabetic retinopathy. Diabetes Mellitus. 2024;27(5):480–486. doi: https://doi.org/10.14341/dm13165Sayin N, Kara N, Pekel G. Ocular complications of diabetes mellitus. World J Diabetes. 2015;6(1):92–108. doi: https://doi.org/10.4239/wjd.v6.i1.92Sayin N, Kara N, Pekel G. Ocular complications of diabetes mellitus. World J Diabetes. 2015;6(1):92–108. doi: https://doi.org/10.4239/wjd.v6.i1.92Li W, Huang E, Gao S. Type 1 Diabetes Mellitus and Cognitive Impairments: A Systematic Review. J Alzheimers Dis. 2017;57(1):29–36. doi: https://doi.org/10.3233/jad-161250Li W, Huang E, Gao S. Type 1 Diabetes Mellitus and Cognitive Impairments: A Systematic Review. J Alzheimers Dis. 2017;57(1):29–36. doi: https://doi.org/10.3233/jad-161250Dong C, Wu G, Li H, et al. Type 1 and type 2 diabetes mortality burden: Predictions for 2030 based on Bayesian age-periodcohort analysis of China and global mortality burden from 1990 to 2019. J Diabetes Investig. 2024;15(5):623–633. doi: https://doi.org/10.1111/jdi.14146Dong C, Wu G, Li H, et al. Type 1 and type 2 diabetes mortality burden: Predictions for 2030 based on Bayesian age-periodcohort analysis of China and global mortality burden from 1990 to 2019. J Diabetes Investig. 2024;15(5):623–633. doi: https://doi.org/10.1111/jdi.14146Tomic D, Harding JL, Jenkins AJ, et al. The epidemiology of type 1 diabetes mellitus in older adults. Nat Rev Endocrinol. 2025;21(2):92–104. doi: https://doi.org/10.1038/s41574-024-01046-zTomic D, Harding JL, Jenkins AJ, et al. The epidemiology of type 1 diabetes mellitus in older adults. Nat Rev Endocrinol. 2025;21(2):92–104. doi: https://doi.org/10.1038/s41574-024-01046-zWang M, Pugh SM, Daboul J, et al. IGF-1 Acts through Kiss1- expressing Cells to Influence Metabolism and Reproduction. bioRxiv. 2024. doi: https://doi.org/10.1101/2024.07.02.601722Wang M, Pugh SM, Daboul J, et al. IGF-1 Acts through Kiss1- expressing Cells to Influence Metabolism and Reproduction. bioRxiv. 2024. doi: https://doi.org/10.1101/2024.07.02.601722Atta SE, Hadi MA, Shakir OY, et al. Evaluation of asprosin levels in growth hormone-deficient children. Journal of Krishna Institute of Medical Sciences University. 2024;13:65–73.Atta SE, Hadi MA, Shakir OY, et al. Evaluation of asprosin levels in growth hormone-deficient children. Journal of Krishna Institute of Medical Sciences University. 2024;13:65–73.Shapiro MR, Peters LD, Brown ME, et al. Insulin-like Growth Factor-1 Synergizes with IL-2 to Induce Homeostatic Proliferation of Regulatory T Cells. J Immunol. 2023;211(7):1108–1122. doi: https://doi.org/10.4049/jimmunol.2200651Shapiro MR, Peters LD, Brown ME, et al. Insulin-like Growth Factor-1 Synergizes with IL-2 to Induce Homeostatic Proliferation of Regulatory T Cells. J Immunol. 2023;211(7):1108–1122. doi: https://doi.org/10.4049/jimmunol.2200651Shapiro MR, Wasserfall CH, McGrail SM, et al. Insulin-Like Growth Factor Dysregulation Both Preceding and Following Type 1 Diabetes Diagnosis. Diabetes. 2020;69(3):413–423. doi: https://doi.org/10.2337/db19-0942Shapiro MR, Wasserfall CH, McGrail SM, et al. Insulin-Like Growth Factor Dysregulation Both Preceding and Following Type 1 Diabetes Diagnosis. Diabetes. 2020;69(3):413–423. doi: https://doi.org/10.2337/db19-0942Szydlowska-Gladysz J, Gorecka AE, Stepien J, et al. IGF-1 and IGF-2 as Molecules Linked to Causes and Consequences of Obesity from Fetal Life to Adulthood: A Systematic Review. Int J Mol Sci. 2024;25(7):3966. doi: https://doi.org/10.3390/ijms25073966Szydlowska-Gladysz J, Gorecka AE, Stepien J, et al. IGF-1 and IGF-2 as Molecules Linked to Causes and Consequences of Obesity from Fetal Life to Adulthood: A Systematic Review. Int J Mol Sci. 2024;25(7):3966. doi: https://doi.org/10.3390/ijms25073966Pustelny K, Grygier P, Barzowska A, et al. Binding mechanism and biological effects of flavone DYRK1A inhibitors for the design of new antidiabetics. Sci Rep. 2023;13(1):18114. doi: https://doi.org/10.1038/s41598-023-44810-3Pustelny K, Grygier P, Barzowska A, et al. Binding mechanism and biological effects of flavone DYRK1A inhibitors for the design of new antidiabetics. Sci Rep. 2023;13(1):18114. doi: https://doi.org/10.1038/s41598-023-44810-3Tekle M, Rassi DM, Donadi EA, et al. Alterations in the IGF-System and Antioxidant Biomarkers in Young Brazilian Adults with Type 1 Diabetes: An Analysis of Cardiovascular Risk Factors. Antioxidants (Basel). 2025;14(12):1514. doi: https://doi.org/10.3390/antiox14121514Tekle M, Rassi DM, Donadi EA, et al. Alterations in the IGF-System and Antioxidant Biomarkers in Young Brazilian Adults with Type 1 Diabetes: An Analysis of Cardiovascular Risk Factors. Antioxidants (Basel). 2025;14(12):1514. doi: https://doi.org/10.3390/antiox14121514Garla V, Sonani H, Palabindala V, Gomez-Sanchez C, Subauste J, Lien LF. Non-islet Cell Hypoglycemia: Case Series and Review of the Literature. Front Endocrinol (Lausanne). 2019;10:316. doi: https://doi.org/10.3389/fendo.2019.00316Garla V, Sonani H, Palabindala V, Gomez-Sanchez C, Subauste J, Lien LF. Non-islet Cell Hypoglycemia: Case Series and Review of the Literature. Front Endocrinol (Lausanne). 2019;10:316. doi: https://doi.org/10.3389/fendo.2019.00316Rhyu J, Yu R. Newly discovered endocrine functions of the liver. World J Hepatol. 2021;13(11):1611–1628. doi: https://doi.org/10.4254/wjh.v13.i11.1611Rhyu J, Yu R. Newly discovered endocrine functions of the liver. World J Hepatol. 2021;13(11):1611–1628. doi: https://doi.org/10.4254/wjh.v13.i11.1611Choi E, Duan C, Bai XC. Regulation and function of insulin and insulin-like growth factor receptor signalling. Nat Rev Mol Cell Biol. 2025;26(7):558–580. doi: https://doi.org/10.1038/s41580-025-00826-3Choi E, Duan C, Bai XC. Regulation and function of insulin and insulin-like growth factor receptor signalling. Nat Rev Mol Cell Biol. 2025;26(7):558–580. doi: https://doi.org/10.1038/s41580-025-00826-3Sobhi W, Derguine R, Boucheffa S, et al. Type 1 diabetes and oxidative stress markers. American Heart Journal. 2021;242:174. doi: https://doi.org/10.1016/j.ahj.2021.10.070Sobhi W, Derguine R, Boucheffa S, et al. Type 1 diabetes and oxidative stress markers. American Heart Journal. 2021;242:174. doi: https://doi.org/10.1016/j.ahj.2021.10.070Biadgo B, Tamir W, Ambachew S. Insulin-like Growth Factor and its Therapeutic Potential for Diabetes Complications - Mechanisms and Metabolic Links: A Review. Rev Diabet Stud. 2020;16(1):24–34. doi: https://doi.org/10.1900/rds.2020.16.24Biadgo B, Tamir W, Ambachew S. Insulin-like Growth Factor and its Therapeutic Potential for Diabetes Complications - Mechanisms and Metabolic Links: A Review. Rev Diabet Stud. 2020;16(1):24–34. doi: https://doi.org/10.1900/rds.2020.16.24Casellas A, Mallol C, Salavert A, et al. Insulin-like Growth Factor 2 Overexpression Induces β-Cell Dysfunction and Increases Beta-cell Susceptibility to Damage. J Biol Chem. 2015;290(27):16772–16785. doi: https://doi.org/10.1074/jbc.m115.642041Casellas A, Mallol C, Salavert A, et al. Insulin-like Growth Factor 2 Overexpression Induces β-Cell Dysfunction and Increases Beta-cell Susceptibility to Damage. J Biol Chem. 2015;290(27):16772–16785. doi: https://doi.org/10.1074/jbc.m115.642041Zhong T, Li X, Lei K, et al. TGF-β-mediated crosstalk between TIGIT+ Tregs and CD226+CD8+ T cells in the progression and remission of type 1 diabetes. Nat Commun. 2024;15(1):8894. doi: https://doi.org/10.1038/s41467-024-53264-8Zhong T, Li X, Lei K, et al. TGF-β-mediated crosstalk between TIGIT+ Tregs and CD226+CD8+ T cells in the progression and remission of type 1 diabetes. Nat Commun. 2024;15(1):8894. doi: https://doi.org/10.1038/s41467-024-53264-8Greenhill C. IGFs potential biomarkers for type 1 diabetes mellitus. Nat Rev Endocrinol. 2020;16(3):130–131. doi: https://doi.org/10.1038/s41574-020-0317-0Greenhill C. IGFs potential biomarkers for type 1 diabetes mellitus. Nat Rev Endocrinol. 2020;16(3):130–131. doi: https://doi.org/10.1038/s41574-020-0317-0Sharma A, Purohit S, Sharma S, et al. IGF-Binding Proteins in Type-1 Diabetes Are More Severely Altered in the Presence of Complications. Front Endocrinol (Lausanne). 2016;7:2. doi: https://doi.org/10.3389/fendo.2016.00002Sharma A, Purohit S, Sharma S, et al. IGF-Binding Proteins in Type-1 Diabetes Are More Severely Altered in the Presence of Complications. Front Endocrinol (Lausanne). 2016;7:2. doi: https://doi.org/10.3389/fendo.2016.00002Song F, Zhou XX, Hu Y, et al. The Roles of Insulin-Like Growth Factor Binding Protein Family in Development and Diseases. Adv Ther. 2021;38:885–903. doi: https://doi.org/10.1007/s12325-020-01581-xSong F, Zhou XX, Hu Y, et al. The Roles of Insulin-Like Growth Factor Binding Protein Family in Development and Diseases. Adv Ther. 2021;38:885–903. doi: https://doi.org/10.1007/s12325-020-01581-xLeRoith D, Holly JMP, Forbes BE. Insulin-like growth factors: Ligands, binding proteins, and receptors. Mol Metab. 2021;52:101245. doi: https://doi.org/10.1016/j.molmet.2021.101245LeRoith D, Holly JMP, Forbes BE. Insulin-like growth factors: Ligands, binding proteins, and receptors. Mol Metab. 2021;52:101245. doi: https://doi.org/10.1016/j.molmet.2021.101245Santi E, Tascini G, Toni G, Berioli MG, Esposito S. Linear Growth in Children and Adolescents with Type 1 Diabetes Mellitus. Int J Environ Res Public Health. 2019;16(19):3677. doi: https://doi.org/10.3390/ijerph16193677Santi E, Tascini G, Toni G, Berioli MG, Esposito S. Linear Growth in Children and Adolescents with Type 1 Diabetes Mellitus. Int J Environ Res Public Health. 2019;16(19):3677. doi: https://doi.org/10.3390/ijerph16193677Yuen KCJ, Hjortebjerg R, Ganeshalingam AA, Clemmons DR, Frystyk J. Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intraportal insulin. Front Endocrinol (Lausanne). 2024;15:1456195. doi: https://doi.org/10.3389/fendo.2024.1456195Yuen KCJ, Hjortebjerg R, Ganeshalingam AA, Clemmons DR, Frystyk J. Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intraportal insulin. Front Endocrinol (Lausanne). 2024;15:1456195. doi: https://doi.org/10.3389/fendo.2024.1456195Merimee TJ, Gardner DF, Zapf J, Froesch ER. Effect of glycemic control on serum insulin-like growth factors in diabetes mellitus. Diabetes. 1984;33(8):790–793. doi: https://doi.org/10.2337/diab.33.8.790Merimee TJ, Gardner DF, Zapf J, Froesch ER. Effect of glycemic control on serum insulin-like growth factors in diabetes mellitus. Diabetes. 1984;33(8):790–793. doi: https://doi.org/10.2337/diab.33.8.790Crowley MT, Lonergan E, O’Callaghan P, et al. IGF-2 mediated hypoglycemia and the paradox of an apparently benign lesion: a case report & review of the literature. BMC Endocr Disord. 2022;22(1):262. doi: https://doi.org/10.1186/s12902-022-01175-4Crowley MT, Lonergan E, O’Callaghan P, et al. IGF-2 mediated hypoglycemia and the paradox of an apparently benign lesion: a case report & review of the literature. BMC Endocr Disord. 2022;22(1):262. doi: https://doi.org/10.1186/s12902-022-01175-4Niedra H, Konrade I, Peculis R, et al. Solitary fibrous tumor with IGF-II-induced non-islet cell tumor hypoglycemia: a case report and molecular characterization by nextgeneration sequencing. Front Oncol. 2023;13:1188579. doi: https://doi.org/10.3389/fonc.2023.1188579Niedra H, Konrade I, Peculis R, et al. Solitary fibrous tumor with IGF-II-induced non-islet cell tumor hypoglycemia: a case report and molecular characterization by nextgeneration sequencing. Front Oncol. 2023;13:1188579. doi: https://doi.org/10.3389/fonc.2023.1188579Koloutsou ME, Soura M, Andreikos D, Spandidos DA, Yavropoulou MP, Georgakopoulou VE. Endocrine paraneoplastic syndromes in lung cancer: A call for clinical vigilance (Review). Mol Clin Oncol. 2025;22(4):36. doi: https://doi.org/10.3892/mco.2025.2831Koloutsou ME, Soura M, Andreikos D, Spandidos DA, Yavropoulou MP, Georgakopoulou VE. Endocrine paraneoplastic syndromes in lung cancer: A call for clinical vigilance (Review). Mol Clin Oncol. 2025;22(4):36. doi: https://doi.org/10.3892/mco.2025.2831Carroll PV, Christ ER, Umpleby AM, et al. IGF-I treatment in adults with type 1 diabetes: effects on glucose and protein metabolism in the fasting state and during a hyperinsulinemiceuglycemic amino acid clamp. Diabetes. 2000;49(5):789–796. doi: https://doi.org/10.2337/diabetes.49.5.789Carroll PV, Christ ER, Umpleby AM, et al. IGF-I treatment in adults with type 1 diabetes: effects on glucose and protein metabolism in the fasting state and during a hyperinsulinemiceuglycemic amino acid clamp. Diabetes. 2000;49(5):789–796. doi: https://doi.org/10.2337/diabetes.49.5.789Khan MU, Mubeen M, Chohan HK, et al. Correlation of Fasting Blood Sugar and Glycated Hemoglobin (HbA1c) With Thiamine Levels in Diabetic Patients. Cureus. 2023;15(9):e46178. doi: https://doi.org/10.7759/cureus.46178Khan MU, Mubeen M, Chohan HK, et al. Correlation of Fasting Blood Sugar and Glycated Hemoglobin (HbA1c) With Thiamine Levels in Diabetic Patients. Cureus. 2023;15(9):e46178. doi: https://doi.org/10.7759/cureus.46178Shapiro MR, Atkinson MA, Brusko TM. Pleiotropic roles of the insulin-like growth factor axis in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2019;26(4):188–194. doi: https://doi.org/10.1097/med.0000000000000484Shapiro MR, Atkinson MA, Brusko TM. Pleiotropic roles of the insulin-like growth factor axis in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2019;26(4):188–194. doi: https://doi.org/10.1097/med.0000000000000484Kubo H, Sawada S, Satoh M, et al. Insulin-like growth factor-1 levels are associated with high comorbidity of metabolic disorders in obese subjects; a Japanese single-center, retrospective-study. Sci Rep. 2022;12(1):20130. doi: https://doi.org/10.1038/s41598-022-23521-1Kubo H, Sawada S, Satoh M, et al. Insulin-like growth factor-1 levels are associated with high comorbidity of metabolic disorders in obese subjects; a Japanese single-center, retrospective-study. Sci Rep. 2022;12(1):20130. doi: https://doi.org/10.1038/s41598-022-23521-1Dynkevich Y, Rother KI, Whitford I, et al. Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. Endocr Rev. 2013;34(6):798–826. doi: https://doi.org/10.1210/er.2012-1033Dynkevich Y, Rother KI, Whitford I, et al. Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. Endocr Rev. 2013;34(6):798–826. doi: https://doi.org/10.1210/er.2012-1033Yan N, Yan W, Deng Z, et al. A metabolic-inflammatory burden phenotype associated with urinary glucose in colorectal cancer. Front Cell Dev Biol. 2026;14:1797508. doi: https://doi.org/10.3389/fcell.2026.1797508Yan N, Yan W, Deng Z, et al. A metabolic-inflammatory burden phenotype associated with urinary glucose in colorectal cancer. Front Cell Dev Biol. 2026;14:1797508. doi: https://doi.org/10.3389/fcell.2026.1797508Kasprzak A. Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer. Int J Mol Sci. 2021;22(12):6434. doi: https://doi.org/10.3390/ijms22126434Kasprzak A. Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer. Int J Mol Sci. 2021;22(12):6434. doi: https://doi.org/10.3390/ijms22126434Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov. 2007;6(10):821–833. doi: https://doi.org/10.1038/nrd2359Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov. 2007;6(10):821–833. doi: https://doi.org/10.1038/nrd2359Hoeflich A, Russo VC. Physiology and pathophysiology of IGFBP-1 and IGFBP-2 - consensus and dissent on metabolic control and malignant potential. Best Pract Res Clin Endocrinol Metab. 2015;29(5):685–700. doi: https://doi.org/10.1016/j.beem.2015.07.002Hoeflich A, Russo VC. Physiology and pathophysiology of IGFBP-1 and IGFBP-2 - consensus and dissent on metabolic control and malignant potential. Best Pract Res Clin Endocrinol Metab. 2015;29(5):685–700. doi: https://doi.org/10.1016/j.beem.2015.07.002Juiz-Valiña P, Pena-Bello L, Cordido M, et al. Altered GH-IGF-1 Axis in Severe Obese Subjects is Reversed after Bariatric Surgery-Induced Weight Loss and Related with Low-Grade Chronic Inflammation. J Clin Med. 2020;9(8):2614. doi: https://doi.org/10.3390/jcm9082614Juiz-Valiña P, Pena-Bello L, Cordido M, et al. Altered GH-IGF-1 Axis in Severe Obese Subjects is Reversed after Bariatric Surgery-Induced Weight Loss and Related with Low-Grade Chronic Inflammation. J Clin Med. 2020;9(8):2614. doi: https://doi.org/10.3390/jcm9082614Livingstone C, Borai A. Insulin-like growth factor-II: its role in metabolic and endocrine disease. Clin Endocrinol (Oxf ). 2014;80(6):773–781. doi: https://doi.org/10.1111/cen.12446Livingstone C, Borai A. Insulin-like growth factor-II: its role in metabolic and endocrine disease. Clin Endocrinol (Oxf ). 2014;80(6):773–781. doi: https://doi.org/10.1111/cen.12446Blyth AJ, Kirk NS, Forbes BE. Understanding IGF-II Action through Insights into Receptor Binding and Activation. Cells. 2020;9(10):2276. doi: https://doi.org/10.3390/cells9102276Blyth AJ, Kirk NS, Forbes BE. Understanding IGF-II Action through Insights into Receptor Binding and Activation. Cells. 2020;9(10):2276. doi: https://doi.org/10.3390/cells9102276Livingstone C. The insulin-like growth factor system and nutritional assessment. Scientifica (Cairo). 2012;2012:768731. doi: https://doi.org/10.6064/2012/768731Livingstone C. The insulin-like growth factor system and nutritional assessment. Scientifica (Cairo). 2012;2012:768731. doi: https://doi.org/10.6064/2012/768731Wang X, Zhang Y, Chi K, et al. IGFBP2 induces podocyte apoptosis promoted by mitochondrial damage via integrin α5/FAK in diabetic kidney disease. Apoptosis. 2024;29(7–8):1109–1125. doi: https://doi.org/10.1007/s10495-024-01974-1Wang X, Zhang Y, Chi K, et al. IGFBP2 induces podocyte apoptosis promoted by mitochondrial damage via integrin α5/FAK in diabetic kidney disease. Apoptosis. 2024;29(7–8):1109–1125. doi: https://doi.org/10.1007/s10495-024-01974-1Hong H, Cui ZZ, Zhu L, et al. Central IGF1 improves glucose tolerance and insulin sensitivity in mice. Nutr Diabetes. 2017;7(12):2. doi: https://doi.org/10.1038/s41387-017-0002-0Hong H, Cui ZZ, Zhu L, et al. Central IGF1 improves glucose tolerance and insulin sensitivity in mice. Nutr Diabetes. 2017;7(12):2. doi: https://doi.org/10.1038/s41387-017-0002-0Ata F, Choudry H, Khan AA, et al. A systematic review of literature on Insulin-like growth factor-2-mediated hypoglycaemia in nonislet cell tumours. Endocrinol Diabetes Metab. 2024;7(2):e00471. doi: https://doi.org/10.1002/edm2.471Ata F, Choudry H, Khan AA, et al. A systematic review of literature on Insulin-like growth factor-2-mediated hypoglycaemia in nonislet cell tumours. Endocrinol Diabetes Metab. 2024;7(2):e00471. doi: https://doi.org/10.1002/edm2.471Laron Z, Werner H. Opposing Metabolic Effects of Growth Hormone and IGF-I: Review and Clinical Implications. Endocr Rev. 2025;46(6):877–890. doi: https://doi.org/10.1210/endrev/bnaf022Laron Z, Werner H. Opposing Metabolic Effects of Growth Hormone and IGF-I: Review and Clinical Implications. Endocr Rev. 2025;46(6):877–890. doi: https://doi.org/10.1210/endrev/bnaf022Shimizu M. Subchapter 28C - Insulin-like growth factor-2. In: Ando H, Ukena K, Nagata S, Hrsg. Handbook of Hormones (Second Edition). San Diego: Academic Press; 2021. p. 289–292. doi: https://doi.org/10.1016/b978-0-12-820649-2.00075-9Shimizu M. Subchapter 28C - Insulin-like growth factor-2. In: Ando H, Ukena K, Nagata S, Hrsg. Handbook of Hormones (Second Edition). San Diego: Academic Press; 2021. p. 289–292. doi: https://doi.org/10.1016/b978-0-12-820649-2.00075-9

The authors declare that there are no conflicts of interest present.